Specifically, the types the vaccine protects against are HPV 16, 18, 31, 33, 45, 52, 58 (which cause ~90% of cervical cancer cases worldwide), and types 6 and 11 which case genital warts.
Investigators examined parental hesitancy when discussing human papillomavirus vaccination with providers.
Providers engaging parents hesitant about human papillomavirus vaccination and addressing their concerns can lead to same-day vaccinations.
High-certainty evidence that HPV vaccination may provide protection in adolescent girls and young women aged 15 to 26 years.
The authors concluded, "There is high-certainty evidence that HPV vaccines protect against cervical precancer in adolescent girls and young women aged 15 to 26," while also indicated that future studies should have long-term follow-up.
Investigators sought to determine the link between HPV vaccination and the risk of developing multiple sclerosis.
Based on these data and the potential change in follow-up care, the HPV mRNA assay should not be used for a primary screening tool for cervical cancer.
The HR-HPV types covered by the nonavalent HPV vaccine had similar clearance rates to HR-HPV types not included, and women infected with multiple anogenital HR-HPV types had lower rates of clearance than women infected with only 1 type.
Adolescent consent may help minimize delays in vaccination and reduce the overall incidence of cervical, oropharyngeal, and anal cancers.
A bundled intervention including communication skills training and performance feedback may improve human papillomavirus vaccination.
For adolescents, a health care professional HPV vaccine communication intervention is associated with improved HPV vaccine series initiation and completion.
Study confirms HPV16 as an important determinant of high-grade lesions and supports its place as a priority for anal cancer prevention.
Deintensification of treatment from chemoradiotherapy to one modality may compromise safety in patients with human papillomavirus (HPV)+ stage 1 or 2 oropharyngeal cancer.
The limitations of herd protection for vaccine-type HPV was examined in a recent study.
Study was the first to examine the geographical variation of seminal HPV prevalence, showing a relatively high prevalence in fertility clinic attendees when compared to the general population.
For patients with HPV-associated cancers, there are large disparities in survival based on sex, race, and age.
Successive negative HPV and cytology co-testing is linked decrease risks of cervical cancer.
Findings inform further refinement of cervical cancer screening algorithms for vaccinated populations.
Incidence of juvenile-onset respiratory papillomatosis declined with the introduction of a HPV vaccination program.
Many US physicians recommended primary HPV testing for women of all ages, contrary to guidelines which limit this screening approach to women ≥25 years old.
The incidence of HPV-related oropharyngeal squamous cell carcinoma has increased in men dramatically and that increase is projected to continue until 2060.
Rajesh T. Gandhi, MD, discusses management of coinfections, including HPV and sexually transmitted infections, in people with HIV.
From 2009-2010 to 2013-2014, there was a decrease in the prevalence of vaccine-type human papillomavirus among unvaccinated young women, which suggests they are beginning to benefit from herd immunity.
Inadvertent administration of the quadrivalent HPV vaccine during periconception or pregnancy was not associated with additional risk to mothers and their infants.
Human papillomavirus vaccine initiation rates are low among young cancer survivors.
Patients with HPV-associated oropharyngeal squamous cell carcinoma have higher 5-year overall survival rates after surgery.
Women with HIV are more likely to experience progressive cervical changes.
Survivors of anal cancer have an elevated risk of HPV-related second primary malignancies.
Maternal education, Hispanic ethnicity, and provider recommendations are associated with parental intent to vaccinate adolescents against HPV.
Two rather than 3 doses of the human papillomavirus vaccine is enough to protect against genital warts in preteens and teens.
Sign Up for Free e-newsletters
Infectious Disease Advisor Articles
- Clinicians Warn That Zika Virus May Still Be an Area of Concern for Travelers
- Ceftazidime/Avibactam an Effective Option in Serious Gram-Negative Infections
- Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy
- Inappropriate Prescribing of Antibiotics High in Urgent Care Centers
- Fixed-Dose Bictegravir Regimen: A Safe Alternative in Adults With HIV-1
- Universal Purchase Programs in the United States May Not Effectively Increase Vaccination Rates
- Tick-Caused Meat Allergy on the Rise in the United States
- Prognostic Biomarkers to Guide Antibiotic Therapy in Critically Ill Patients
- Sofosbuvir/Velpatavir Effective for HCV-Infected Liver Transplant Recipients
- Should Metronidazole Be Recommended for Mild Clostridium difficile Infections?
- Pegylated Interferon, Ribavirin May Improve LV Diastolic Dysfunction in Chronic Hepatitis C
- Automated HIV/Hepatitis C Screening Protocol Demonstrates High Efficacy
- Factors Increasing Risk for Hemorrhagic Stroke After Infective Endocarditis
- Salmonella Outbreak Linked to Hy-Vee Spring Pasta Salad
- Harms Reporting Limited in Trials of Prebiotics, Probiotics, Synbiotics